Hims & Hers Expands Into Menopause Care With Personalized Treatment Plans

Hims & Hers Health (NYSE: HIMS) ticked up 2.85% to $55.56 after announcing a major expansion into perimenopause and menopause treatments — a product line that investors have anticipated for months.

The company said it will now offer personalized treatment plans for menopause and perimenopause that may include prescription pills, patches, or creams. Additional therapies are expected to roll out in 2026 as the company deepens its women’s health portfolio.

Recent Expansions in Hormonal Care

Last month, Hims announced it would begin offering testosterone treatments, including Kyzatrex, an FDA-approved oral testosterone therapy through a partnership with Marius Pharmaceuticals.

The expansion marks a strategic move to diversify beyond weight-loss drugs, particularly after limitations emerged in selling compounded versions of Novo Nordisk’s (NVO) blockbuster GLP-1 treatments as branded supply improved.

Market Context & Leadership Changes

Hims recently reported its first sequential decline in quarterly sales, missing Wall Street’s revenue expectations. However, analysts remain positive on the company’s direct-to-consumer telehealth strategy and growing cross-sell potential.

Earlier this month, COO Nader Kabbani, a former Amazon executive, announced his departure after less than nine months in the role.

“This expansion into menopause care underscores our long-term vision to support people across every stage of hormonal health,” the company said in a statement.